Liquidia Technologies Inc Cash Flow Conversion Efficiency
Liquidia Technologies Inc cash flow conversion efficiency. Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has a cash flow conversion efficiency ratio of 0.411x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($80.24 Million) by net assets ($195.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Liquidia Technologies Inc (2016–2025)
Cash flow conversion efficiency of Liquidia Technologies Inc from 2016 to 2025. This chart illustrates how Liquidia Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Liquidia Technologies Inc (LQDA) stock price for real-time trading data and today's change.
Liquidia Technologies Inc Cash Flow Conversion Ratio Explained
Liquidia Technologies Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Liquidia Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liquidia Technologies Inc ranked by their cash flow conversion efficiency. Also see LQDA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TUI AG
F:TUI1
|
0.838x |
|
GRUPO SIM. S.A.B. B ADR/3
F:GSM
|
-0.007x |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
0.044x |
|
Copa Holdings S.A
F:C2H
|
0.144x |
|
Fujian Wanchen Biotechnology Co. Ltd
SHE:300972
|
N/A |
|
Jinneng Holding Shanxi Coal Industry Co Ltd
SHG:601001
|
0.030x |
|
Cadence Bancorp
NYSE:CADE
|
0.031x |
|
Badger Meter Inc
NYSE:BMI
|
0.039x |
Annual Cash Flow Conversion Efficiency for Liquidia Technologies Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Liquidia Technologies Inc from 2016 to 2025. Review cash generation quality of Liquidia Technologies Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.75 Million | $-35.69 Million | -0.797x | +34.03% |
| 2024-12-31 | $77.28 Million | $-93.42 Million | -1.209x | -37.56% |
| 2023-12-31 | $47.29 Million | $-41.56 Million | -0.879x | -177.98% |
| 2022-12-31 | $90.42 Million | $-28.59 Million | -0.316x | +39.37% |
| 2021-12-31 | $65.27 Million | $-34.03 Million | -0.521x | +31.53% |
| 2020-12-31 | $71.09 Million | $-54.14 Million | -0.762x | +44.87% |
| 2019-12-31 | $34.95 Million | $-48.28 Million | -1.382x | +18.89% |
| 2018-12-31 | $18.69 Million | $-31.83 Million | -1.703x | -336.26% |
| 2017-12-31 | $-33.69 Million | $-24.29 Million | 0.721x | -5.68% |
| 2016-12-31 | $-18.25 Million | $-13.95 Million | 0.764x | -- |
About Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung diseas… Read more